Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
11:01am, Wednesday, 30'th Jul 2025
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
Can Novo Nordisk's New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
09:03am, Wednesday, 30'th Jul 2025
The company's first non-Danish leader, Maziar Mike Doustdar, will face a challenging landscape in the U.S.
Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?
09:00am, Wednesday, 30'th Jul 2025
The sharp Novo Nordisk A/S stock drop reflects real concerns: slowing demand, CEO transition, rising competition, and macro headwinds. GLP-1 hype is fading as insurance coverage wanes, compounded gene
Novo Nordisk: After the profit warning what next?
08:22am, Wednesday, 30'th Jul 2025
Shares in Novo Nordisk (NYSE:NVO) are under the spotlight after a surprise profit warning, which, while denting the share price, failed to the wreak the damage some might have feared. That said, the 3
Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.
08:02am, Wednesday, 30'th Jul 2025
The maker of Ozempic and Wegovy just had its worst day since Black Monday 1987
Novo Nordisk: Catch That Falling Knife
06:36am, Wednesday, 30'th Jul 2025
Novo Nordisk's stock has dropped over 20%, but its core business remains strong and diversified, making this an attractive entry point for investors. Despite increased GLP-1 competition and lowered gu
Novo Nordisk shares fall further as new CEO faces US challenges
05:37am, Wednesday, 30'th Jul 2025
Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of persistent competition from copycat drugs in the U.S., a day after a profit warning and the naming of a new CE
Novo Nordisk needs something new, outside of weigh-loss drugs, says BMO's Seigerman
06:19pm, Tuesday, 29'th Jul 2025
Evan Seigerman, BMO Capital Markets, joins 'Fast Money' to talk to Nono Nordisk sinking on guidance cut.
Novo Nordisk: Massive Overreaction Presents An Opportunity
05:28pm, Tuesday, 29'th Jul 2025
Novo Nordisk's sharp selloff is an overreaction; long-term fundamentals remain solid despite lowered guidance and a sudden CEO change. US market headwinds, competitive pressure from Eli Lilly and tele
Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing
03:30pm, Tuesday, 29'th Jul 2025
Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade, despite strong double-digit sales and profit growth. The market is concerned about headwinds for semaglutide (Weg
Wegovy maker Novo's profit warning wipes out $70B in market value after shares plunge 30%
03:09pm, Tuesday, 29'th Jul 2025
Novo, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO
Why NovoCure Stock Is Cratering Today
02:29pm, Tuesday, 29'th Jul 2025
Shares of Novo Nordisk (NVO -21.28%) are plunging on Tuesday, down 21% as of 2:10 p.m. ET. The drop comes as the S&P 500 (^GSPC) and the Nasdaq Composite (^IXIC) both lost 0.3%.
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
12:41pm, Tuesday, 29'th Jul 2025
Health-related stocks are not having a good day. First, America's largest health insurance provider, UnitedHealth Group (NYSE: UNH), saw its stock drop more than 4% this morning after the company anno
Novo's new CEO faces sceptical investors with Wegovy US sales in focus
11:55am, Tuesday, 29'th Jul 2025
Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales growth and sliding share price. He first will need to win over sceptical in
Don't buy the dip in Novo Nordisk yet, says Mizuho's Jared Holz
11:47am, Tuesday, 29'th Jul 2025
Jared Holz, Mizuho health care equity strategist, joins 'Money Movers' to discuss Novo Nordisk sinking on guidance cut and his outlook for the stock.
